Indeed, even if the co-existence of KRAS and EGFR mutations could be interpreted as double mutation occurring in the crizotinib-resistant tumor cells, the possibility of different tumor clones with activation of EGFR and KRAS signaling as different mechanisms of crizotinib-resistance appeared to be an alternative, perhaps more likely explanation. This evidence concerns the gene EGFR and neoplasm.